Rachel Meyers, Ph.D.
“What keeps me believing in Third Rock is the diligence with which the TRV team explores an area of science before launching a company.”
At Third Rock, Rachel focuses on drug discovery and development opportunities across our portfolio. She appreciates being given the time and resources to thoroughly explore an area of science before launching a company in order to create a path for the science to ultimately reach patients. She is driven by the belief that there is a never-ending stream of interesting and important questions to answer that the biotech industry is well suited to tackle. She is fulfilled knowing that the effort exerted in exploring these questions will have an impact on the lives of people around the world.
Rachel consults on RNAi therapies, serves on a number of Scientific Advisory Boards, is listed as an inventor in many patents and patent applications, and has published numerous peer-reviewed publications. She completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her Ph.D. from MIT in the field of in vitro transcription.